Trial Profile
A Multi-Center, Randomized, Double-Blind, Three-Arm, Parallel-Group Trial to Assess the Efficacy and Safety of NTRA-9620 in Infants With Short Bowel Syndrome (SBS) Following Surgical Resection
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs NTRA 9620 (Primary)
- Indications Short bowel syndrome
- Focus Therapeutic Use
- Acronyms GIFT
- Sponsors Nutrinia
- 21 Mar 2019 Status changed from active, no longer recruiting to discontinued.
- 18 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Apr 2017 Status changed from not yet recruiting to recruiting.